Clinical trial
Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123)…
NCT00441701 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00441701 |
|---|---|
| Title | Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012) |
| Official title | Safety and Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease |
| Intervention type | Drug |
| Interventions | Navarixin 1 mg, Navarixin 10 mg, Placebo to match navarixin, Rescue medication |
| Enrollment | 99 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Mar 1, 2007 |
| Last update posted | Jan 2, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: